Immutep Limited IMMP
Immutep Limited (Nasdaq: IMMP) is an oncology drug developer. Its lead program, eftilagimod alfa (efti, IMP321), is in Phase 2 for Head and neck squamous cell carcinoma (HNSCC), 1st line, PD-L1 CPS <1. Its next catalyst on record is eftilagimod alfa: Immutep targets study start for registration-directed clinical trials of efti in HNSCC (CPS <1) and neoadjuvant STS during H2 CY27. (H2 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: eftilagimod alfa — Immutep targets study start for registration-directed clinical trials of efti in HNSCC (CPS <1) and neoadjuvant STS during H2 CY27. (H2 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| eftilagimod alfa (efti, IMP321) | 1st line non-small cell lung cancer (NSCLC) | protein/peptide | Phase 3 |
| eftilagimod alfa (efti, IMP321) | 1st line head and neck squamous cell carcinoma (PD-L1 CPS <1) | protein/peptide | Phase 2 |
| eftilagimod alfa (efti, IMP321) | Metastatic breast cancer | protein/peptide | Phase 2 |
| eftilagimod alfa (efti, IMP321) | Soft tissue sarcoma (neoadjuvant with radiotherapy and pembrolizumab) | protein/peptide | Phase 2 |
| IMP701 (LAG525; ieramilimab) | Various (previously licensed to Novartis) | antibody | Phase 1 |
| IMP761 | Autoimmune disease | antibody | Pre-clinical |
| IMP731 | Various (previously licensed) | antibody | Pre-clinical |
Recent results and decisions
- Nov 2, 2026discontinued TACTI-004 Phase III trial in first-line NSCLC was discontinued early following root cause analysis that identified structural differences between efti used in TACTI-004 and efti used in earlier successful clinical studies.
Following the early discontinuation of the TACTI-004 study, Immutep has been conducting a detailed root cause analysis.
Filing - Nov 2, 2026positive IMP761 Phase I trial met its primary endpoint demonstrating favorable safety and tolerability, with statistically significant pharmacodynamic activity including reduced inflammatory responses.
The single ascending dose part of the study met its primary endpoint, demonstrating favourable safety and tolerability in healthy volunteers, with IMP761 well tolerated across all dose levels tested.
Filing - Nov 2, 2026met EFTISARC-NEO Phase II trial in resectable STS met its primary endpoint with median 51.5% tumor hyalinization/fibrosis, significantly exceeding the prespecified 35% target.
The investigator-initiated EFTISARC-NEO Phase II trial evaluating efti in combination with radiotherapy and KEYTRUDA® in the neoadjuvant setting for resectable STS has met its primary endpoint, with a median 51.5% tumour hyalinization/fibrosis in the evaluable population (N=38), significantly exceed
Filing
8 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.